NR1H3 and diabetes mellitus: Interestingly, oxepinamides D-G and H−K (12–15, 32–35) all selectively showed transactivation effects on LXRα, which implied their potential use as novel LXR agonists in the treatment of atherosclerosis, diabetes, and Alzheimer’s disease.